By Katherine Hamilton
Kazia Therapeutics stock retreated Tuesday after the FDA said it could consider standard, but not accelerated, approval for the company's brain cancer drug.
Shares of the oncology-focused drug company fell 26% to $2.28 in morning trading. The stock is down about 48% this year.
The drug, called paxalisib, is designed to treat the brain cancer glioblastoma. It showed clinically meaningful improvement in overall survival during a July trial, and Kazia's stock more than quadrupled.
The FDA said it would generally not approve accelerated approval for pazalisib, Kazia said Tuesday. It could consider support for a standard approval.
The FDA said some of the overall survival data would be supportive for designing a pivotal registrational study to pursue standard approval. The agency agreed with Kazia on aspects of a phase 3 study, including patient population and primary endpoint, Kazia said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 31, 2024 10:11 ET (15:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。